.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,223,510

« Back to Dashboard
Patent 5,223,510 protects MULTAQ and is included in one NDA. There has been one Paragraph IV challenge on Multaq. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has forty patent family members in thirty-two countries.

Summary for Patent: 5,223,510

Title: Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them
Abstract:The subject of the invention is benzofuran, benzothiophene, indole or indolizine compounds of general formula: ##STR1## in which: Het represents one of the groups: ##STR2## in which T,T' and T"represent particularly a group: ##STR3## R and R.sub.a, identical or different, represent X represent --O-- or --S-- Y represents a radical ##STR4## These compounds are useful as medecines particularly for the treatment of pathological syndroms of the cardio-vascular system.
Inventor(s): Gubin; Jean (Brussels, BE), Chatelain; Pierre (Brussels, BE), Lucchetti; Jean (Chastre, BE), Rosseels; Gilbert (Wemmel, BE), Inion; Henri (Wemmel, BE)
Assignee: Sanofi (Paris, FR)
Application Number:07/736,580
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009RXYes5,223,510► subscribeYY REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009RXYes5,223,510► subscribeYY REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,223,510

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France90 10036Aug 06, 1990

International Patent Family for Patent: 5,223,510

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria145645► subscribe
Australia648569► subscribe
Australia8142891► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc